Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"EC 2.7.10.1"
topic_facet:"Quinazolines"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22EC+2.7.10.1%22&filter%5B%5D=topic_facet%3A%22Quinazolines%22&lookfor=%22Nilsson%2C+Monique+B%22&type=Person
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22EC+2.7.10.1%22&filter%5B%5D=topic_facet%3A%22Quinazolines%22&lookfor=%22Nilsson%2C+Monique+B%22&type=Person
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22EC+2.7.10.1%22&filter%5B%5D=topic_facet%3A%22Quinazolines%22&lookfor=%22Nilsson%2C+Monique+B%22&type=Person
PubPharm (7)
1
Poziotinib for EGFR exon 20-mutant NSCLC : Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
enthalten in:
Cancer cell
| 2022
von
Elamin, Y.
|
Robichaux, J.
|
Carter, B.
| +24
CommentIn: Cancer Cell. 2022 Jul 11;40(7):705-708. - PMID 35820394
Wird geladen...
2
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
enthalten in:
Cancer cell
| 2019
von
Robichaux, J.
|
Elamin, Y.
|
Vijayan, R.
| +28
ErratumIn: Cancer Cell. 2020 Mar 16;37(3):420. - PMID 32183953
Wird geladen...
3
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer
enthalten in:
Nature medicine
| 2018
von
Robichaux, J.
|
Elamin, Y.
|
Tan, Z.
| +21
CommentIn: Nat Rev Clin Oncol. 2018 Jul;15(7):404. - PMID 29743681
Wird geladen...
4
Stress hormones promote EGFR inhibitor resistance in NSCLC : Implications for combinations with β-blockers
enthalten in:
Science translational medicine
| 2017
von
Nilsson, M.
|
Sun, H.
|
Diao, L.
| +22
CommentIn: Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S117-S122. - PMID 29782563
Wird geladen...
5
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib
enthalten in:
Clinical cancer research : an official journal of the American Association for Cancer Research
| 2016
von
Nilsson, M.
|
Giri, U.
|
Gudikote, J.
| +15
Wird geladen...
6
A novel therapeutic combination for neuroblastoma : the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid
enthalten in:
Cancer
| 2010
von
Zage, P.
|
Zeng, L.
|
Palla, S.
| +4
Wird geladen...
7
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance
enthalten in:
Clinical cancer research : an official journal of the American Association for Cancer Research
| 2009
von
Naumov, G.
|
Nilsson, M.
|
Cascone, T.
| +17
Wird geladen...
1
[1]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Thema: EC 2.7.10.1
Filter aufheben
Thema: Quinazolines
Medienart
7
Aufsätze
7
E-Artikel
7
E-Ressourcen
Zeitschriftentitel
2
Cancer cell
2
Clinical cancer research : an official journal ...
1
Cancer
1
Nature medicine
1
Science translational medicine
Alle anzeigen ...
weniger ...
Thema
EC 2.7.10.1
7
Journal Article
Quinazolines
5
ErbB Receptors
5
Protein Kinase Inhibitors
5
Research Support, N.I.H., Extramural
5
Research Support, Non-U.S. Gov't
3
HM781-36B
3
Piperidines
3
YO460OQ37K
3
vandetanib
2
41UD74L59M
2
Afatinib
2
Clinical Trial, Phase II
2
EC 2.7.11.1
2
Receptor, ErbB-2
2
Receptors, Vascular Endothelial Growth Factor
2
Vascular Endothelial Growth Factor A
1
2S9ZZM9Q9V
1
AMP-Activated Protein Kinase Kinases
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
1
2020-
5
2010-2019
1
2000-2009
Erscheinungsjahr(e)
Von:
Bis:
Sprache
7
Englisch
Haven't found what you're looking for?
Wird geladen...